New emerging roles of the novel hepatokine SERPINB1 in type 2 diabetes mellitus: Crosstalk with β-cell dysfunction and dyslipidemia.
Journal
Translational research : the journal of laboratory and clinical medicine
ISSN: 1878-1810
Titre abrégé: Transl Res
Pays: United States
ID NLM: 101280339
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
07
05
2020
revised:
26
10
2020
accepted:
09
12
2020
pubmed:
17
12
2020
medline:
10
8
2021
entrez:
16
12
2020
Statut:
ppublish
Résumé
Diabetes mellitus (DM) is a devastating metabolic disease. Recently, the cross-talk between insulin-secreting-β-cells and various organs has sparked much interest. SerpinB1 emerged as a novel hepatokine inducing β-cell proliferation. However, its role in type-2-DM (T2DM) patients has not been adequately studied. This study was designed to investigate its circulating levels in subjects with/without T2DM, and to study its association with β-cell function, as well as various glycemic-control and lipid-profile parameters. Anthropometric data and biochemical markers including fasting plasma glucose (FPG), HbA
Identifiants
pubmed: 33326860
pii: S1931-5244(20)30299-1
doi: 10.1016/j.trsl.2020.12.004
pii:
doi:
Substances chimiques
Biomarkers
0
Serpins
0
SERPINB1 protein, human
147416-07-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-12Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.